Explore more Johnson & Johnson sites:
Jump to:
Our Commitment to the Communities Most Impacted by COVID-19
Our Commitment to the Communities Most Impacted by COVID-19
Our Commitment to the Communities Most Impacted by COVID-19
e are investigating multiple doses and dosing regimens of our investigational COVID-19 vaccine candidate to evaluate long-term efficacy.
The Phase 3 clinical trial for our single-dose COVID-19 vaccine candidate, known as ENSEMBLE, enrolled approximately 45,000 participants. We are actively enrolling participants in our ENSEMBLE 2 Phase 3 clinical trial examining a two-dose COVID-19 vaccine regimen.
Driven by our company Credo, we have a responsibility to put the needs and well-being of the patients, families, and communities we serve first. The COVID-19 pandemic is significantly impacting communities of color and older populations and we must ensure these populations are included in the ENSEMBLE studies as study volunteers. Including a diverse and representative group of study volunteers as we are determining the efficacy (whether it works) and safety of an investigational vaccine for the prevention of COVID-19 will ensure that we learn how differences like age, race and ethnicity may impact these measures.
Enrollment Details for the ENSEMBLE Phase 3 Clinical Trial Evaluating a Single-Dose Vaccine Candidate
